These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Induction of micronuclei in peripheral blood lymphocytes of patients treated for rheumatoid or osteo-arthritis of the knee with dysprosium-165 hydroxide macroaggregates or yttrium-90 silicate. Prosser JS; Izard BE; Brown JK; Hetherington EL; Lambrecht RM; Cato L; Wallace M; Whitwell J; Wiseman J; Hoschl R Cytobios; 1993; 73(292):7-15. PubMed ID: 8500348 [TBL] [Abstract][Full Text] [Related]
6. Radiation synovectomy with 165Dy-FHMA: lymph node uptake and radiation dosimetry calculations. Zalutsky MR; Venkatesan PP; English RJ; Shortkroff S; Sledge CB; Adelstein SJ Int J Nucl Med Biol; 1986; 12(6):457-65. PubMed ID: 3710708 [TBL] [Abstract][Full Text] [Related]
7. Treatment of antigen-induced arthritis in rabbits with dysprosium-165-ferric hydroxide macroaggregates. Zuckerman JD; Sledge CB; Shortkroff S; Venkatesan P J Orthop Res; 1989; 7(1):50-60. PubMed ID: 2908912 [TBL] [Abstract][Full Text] [Related]
8. [166Dy]Dy/166Ho hydroxide macroaggregates: an in vivo generator system for radiation synovectomy. Ferro-Flores G; Hernández-Oviedo O; Arteaga de Murphy C; Tendilla JI; Monroy-Guzmán F; Pedraza-López M; Aldama-Alvarado K Appl Radiat Isot; 2004 Dec; 61(6):1227-33. PubMed ID: 15388114 [TBL] [Abstract][Full Text] [Related]
9. Synovectomy of the rheumatoid knee using intra-articular injection of dysprosium-165-ferric hydroxide macroaggregates. Sledge CB; Zuckerman JD; Shortkroff S; Zalutsky MR; Venkatesan P; Snyder MA; Barrett WP J Bone Joint Surg Am; 1987 Sep; 69(7):970-5. PubMed ID: 3654709 [TBL] [Abstract][Full Text] [Related]
10. Repeat radiation synovectomy with dysprosium 165-ferric hydroxide macroaggregates in rheumatoid knees unresponsive to initial injection. Vella M; Zuckerman JD; Shortkroff S; Venkatesan P; Sledge CB Arthritis Rheum; 1988 Jun; 31(6):789-92. PubMed ID: 3382451 [TBL] [Abstract][Full Text] [Related]
11. In vivo stability of ferric hydroxide macroaggregates (FHMA). Is it a suitable carrier for radionuclides used in synovectomy? Chinol M; Vallabhajosula S; Zuckerman JD; Goldsmith SJ Int J Rad Appl Instrum B; 1990; 17(5):479-86. PubMed ID: 2391243 [TBL] [Abstract][Full Text] [Related]
12. Monitoring of the biodistribution and biokinetics of dysprosium-165 ferric hydroxide with a shadow-shield whole-body counter. Pirich C; Prüfert U; Havlik E; Schwarmeis E; Flores J; Kvaternik H; Angelberger P; Aiginger J; Wanivenhaus A; Sinzinger H Eur J Nucl Med; 1997 Apr; 24(4):398-402. PubMed ID: 9096090 [TBL] [Abstract][Full Text] [Related]
13. Intra-articular radiation treatment of rheumatoid synovitis of the ankle with dysprosium-165 ferric hydroxide macroaggregates. Barnes CL; Shortkroff S; Wilson M; Sledge CB Foot Ankle Int; 1994 Jun; 15(6):306-10. PubMed ID: 8075761 [TBL] [Abstract][Full Text] [Related]
14. Treatment of rheumatoid arthritis using radiopharmaceuticals. Zuckerman JD; Sledge CB; Shortkroff S; Venkatesan P Int J Rad Appl Instrum B; 1987; 14(3):211-8. PubMed ID: 3667304 [TBL] [Abstract][Full Text] [Related]
15. A comparative study of the safety and efficacy of dysprosium-165 hydroxide macro-aggregate and yttrium-90 silicate colloid in radiation synovectomy--a multicentre double blind clinical trial. Australian Dysprosium Trial Group. Edmonds J; Smart R; Laurent R; Butler P; Brooks P; Hoschl R; Wiseman J; George S; Lovegrove F; Warwick A Br J Rheumatol; 1994 Oct; 33(10):947-53. PubMed ID: 7921756 [TBL] [Abstract][Full Text] [Related]
16. Preparation and studies with 90Y-labelled particles for use in radiation synovectomy. Pandey U; Mukherjee A; Chaudhary PR; Pillai MR; Venkates M Appl Radiat Isot; 2001 Oct; 55(4):471-5. PubMed ID: 11545499 [TBL] [Abstract][Full Text] [Related]
18. Calculation of beta dosimetry in radiation synovectomy using Monte Carlo simulation (EGS4). Johnson LS; Yanch JC Med Phys; 1993; 20(3):747-54. PubMed ID: 8350831 [TBL] [Abstract][Full Text] [Related]
19. Radiation synovectomy using 165Dy ferric-hydroxide and oxidative DNA damage in patients with different types of arthritis. Pirich C; Pilger A; Schwameis E; Germadnik D; Prüfert U; Havlik E; Lang S; Kvaternik H; Flores JA; Angelberger P; Wanivenhaus A; Rüdiger HW; Sinzinger H J Nucl Med; 2000 Feb; 41(2):250-6. PubMed ID: 10688107 [TBL] [Abstract][Full Text] [Related]
20. Treatment of rheumatoid synovitis of the knee with intraarticular injection of dysprosium 165-ferric hydroxide macroaggregates. Sledge CB; Zuckerman JD; Zalutsky MR; Atcher RW; Shortkroff S; Lionberger DR; Rose HA; Hurson BJ; Lankenner PA; Anderson RJ Arthritis Rheum; 1986 Feb; 29(2):153-9. PubMed ID: 3006701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]